NCT03677973 is a Phase 1 clinical trial of AB680 in Healthy Volunteers, sponsored by Arcus Biosciences, Inc..

Who is sponsoring NCT03677973?

NCT03677973 is sponsored by Arcus Biosciences, Inc..

What drugs are being tested in NCT03677973?

Interventions in NCT03677973: AB680, Placebo.

What condition does NCT03677973 study?

NCT03677973 studies Healthy Volunteers.

Is NCT03677973 still recruiting?

NCT03677973 is currently completed. Last updated 24 May 2024.

Last reviewed 2024-05-24 · How we verify

NCT03677973

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Investigate the Safety of AB680 in Healthy Volunteers

Completed Phase 1 Last updated 24 May 2024

What this trial tests

Phase 1 trial testing AB680 in Healthy Volunteers in 64 participants. Completed in 19 August 2019.

Timeline

16 October 2018

Primary endpoint
19 August 2019

19 August 2019

Quick facts

Lead sponsor	Arcus Biosciences, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	quadruple
Primary purpose	treatment
Enrollment	64
Start date	16 October 2018
Primary completion	19 August 2019
Estimated completion	19 August 2019
Sites	1 location across Australia

Drugs / interventions tested

AB680 — full drug profile →
Placebo

Conditions studied

Healthy Volunteers — all drugs for Healthy Volunteers →

Sponsor

Arcus Biosciences, Inc. — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a double-blind, randomized, placebo-controlled, single- and multiple-ascending dose study to investigate the safety, tolerability, and pharmacokinetic profile of AB680 in healthy volunteers.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Adenosine Metabolism: Emerging Concepts for Cancer Therapy.
Boison D, Yegutkin GG. · · 2019 · cited 251× · PMID 31821783 · DOI 10.1016/j.ccell.2019.10.007
Tuning the Tumor Myeloid Microenvironment to Fight Cancer.
Jahchan NS, Mujal AM, Pollack JL, Binnewies M, et al · · 2019 · cited 101× · PMID 31402908 · DOI 10.3389/fimmu.2019.01611
Inhibition of the Adenosine Pathway to Potentiate Cancer Immunotherapy: Potential for Combinatorial Approaches.
Thompson EA, Powell JD. · · 2021 · cited 61× · PMID 32903139 · DOI 10.1146/annurev-med-060619-023155
Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.
Xu S, Wang C, Yang L, Wu J, et al · · 2023 · cited 40× · PMID 37313405 · DOI 10.3389/fimmu.2023.1199631
An Exceptionally Potent Inhibitor of Human CD73.
Bowman CE, da Silva RG, Pham A, Young SW. · · 2019 · cited 40× · PMID 31334635 · DOI 10.1021/acs.biochem.9b00448
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1 : National Harbor, MD, USA. 6-10 November 2019.
· 2019 · cited 19× · PMID 31694725 · DOI 10.1186/s40425-019-0763-1
Regulation of CD73 on NAD metabolism: Unravelling the interplay between tumour immunity and tumour metabolism.
Zhan J, Huang L, Niu L, Lu W, et al · · 2024 · cited 13× · PMID 39090604 · DOI 10.1186/s12964-024-01755-y
The Role of Metabolism in Tumor Immune Evasion: Novel Approaches to Improve Immunotherapy.
Cruz-Bermúdez A, Laza-Briviesca R, Casarrubios M, Sierra-Rodero B, et al · · 2021 · cited 12× · PMID 33807260 · DOI 10.3390/biomedicines9040361

Verify or expand the search:

Other trials of AB680

Trials testing the same drug.

NCT04660812 — An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participa · Phase 1, PHASE2 · completed
NCT04575311 — A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers · Phase 1 · completed

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting

Other Arcus Biosciences, Inc. trials

Trials by the same sponsor.

NCT06919991 — Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29) · Phase 1 · completed
NCT06608927 — Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Ad · Phase 3 · active not recruiting
NCT06004921 — A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers · Phase 1 · completed
NCT05999513 — A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers · Phase 1 · completed
NCT05411146 — A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant, a New Compound in t · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03677973 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Arcus Biosciences, Inc.
Last refreshed: 24 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03677973.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing